Structure Therapeutics (GPCR) stock
Follow GPCR's trial news. Pro members can get an alert when Structure Therapeutics files news, and see its trials, share raises, and its CEO's filings.
GPCR's Quality Score fell 1 point on Fri, Oct 2, to -7.
What's next for GPCR, and how long its cash lasts
From Structure Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
$1.3B in cash
Dilution on the horizon
- Shelf registration (S-3ASR, filed Aug 6, 2025)
- At-the-market share sales program (424B5, filed May 7, 2026)
Insiders
No open-market buys or sales by its officers or directors in their filings of the last year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why GPCR is down
Structure Therapeutics fell 19.5% over the five sessions to Oct 1.
Biotech stocks fell a median 3.4% and the S&P 500 fell 0.4% in those sessions; Structure Therapeutics fell 19.5%.
−2Long-term trend below a falling 200-day average, down over two years
1 more driver, the timeline, and the peer table, for Pro members
4 more things pulling GPCR's score down, for Pro members
What's next
Expected to report Thu Nov 5, after the close
After its last 4 reports it closed -0.9% on average, higher 1 of 4 times.
What would turn GPCR's score around: 8 things, for Pro members
Here is what Pro members see.
Every stock has a live page like this, GPCR included: the price in real time, the full chart, all 14 checks, and every line of its score.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Nothing is firing on GPCR right now
One per group is shown here.
Also on the chart
- RSI 1416.8
- MACD (12, 26, 9)Below signal
- 50-day average$44.71
- 200-day average$53.52
- ADX 1444.4
- Support$25.59
- Resistance$31.08
- Volume1.1x
How GPCR ranks in Biotech
GPCR is #281 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
EXEL7/1417
AMRX6/1417
GILDOpen for its score
GOSSOpen for its score
GRMLOpen for its score
HALOOpen for its score
GPCR0/14-7
When does GPCR report earnings, and what happens after?
Expected to report Thu Nov 5, after the close (in 34 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026After close | After close | +2.2% | +1.0% | +4.0% |
| May 7, 2026After close | After close | -2.5% | -0.1% | +1.8% |
| Feb 26, 2026After close | After close | -1.0% | -2.7% | -7.8% |
| Nov 6, 2025After close | After close | +0.7% | -1.9% | +4.6% |
About Structure Therapeutics
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of GPCR's score, with the points and the reason
- All 14 checks on GPCR and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on GPCR
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.